The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level. Stable disease (SD) ...

Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist. The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of ...

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) ...

IMUNON (IMNN) announced additional clinical data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its ...

Evaluating colitis treatment efficacy and body composition changes using an IL-12/23 p40 neutralizing antibody, measured ...

The company’s lead asset, ANK-101, is an interleukin-12 (IL-12) physically anchored to aluminum hydroxide. ANK-101 is locally delivered and retained in the tumor microenvironment for several ...